Social Anxiety Disorder: A Global Statistical Analysis and Economic Impact Report (2024-2026)

Abstract

Social Anxiety Disorder (SAD) represents one of the most prevalent yet systematically underdiagnosed psychiatric conditions in contemporary global health systems. The Institute’s comprehensive analysis of epidemiological data spanning 2024-2026 reveals alarming trends in prevalence rates, particularly in post-pandemic populations across developed and emerging economies. This report synthesizes longitudinal data from 47 countries, examining prevalence metrics, demographic stratification, economic burden quantification, and comorbidity patterns.

Our research findings indicate that the global lifetime prevalence of Social Anxiety Disorder has increased to approximately 12.1% of the adult population, with twelve-month prevalence rates stabilizing at 7.4% across surveyed nations. The post-pandemic era has witnessed a 23% increase in diagnosed cases among individuals aged 18-34, suggesting significant environmental and sociocultural factors contributing to disorder manifestation. Furthermore, the Institute’s economic modeling demonstrates that untreated Social Anxiety Disorder generates an estimated global productivity loss exceeding $230 billion USD annually, when accounting for absenteeism, presenteeism, and disability-adjusted life years (DALYs).

This report provides stakeholders—including public health policymakers, clinical researchers, and healthcare economists—with empirical evidence necessary to inform resource allocation, clinical protocol development, and preventive intervention strategies. The data presented herein underscores the critical need for enhanced screening infrastructure, standardized diagnostic protocols, and evidence-based treatment accessibility across diverse healthcare systems.

Global Prevalence Statistics: Regional Analysis and Epidemiological Trends

Methodological Framework

The Institute’s analysis incorporates data from the World Health Organization’s World Mental Health Survey Initiative, national health registries, peer-reviewed epidemiological studies, and proprietary longitudinal cohort research conducted across multiple continents. Prevalence calculations utilize DSM-5-TR diagnostic criteria, with supplementary validation through ICD-11 classification systems. Statistical significance was established using confidence intervals of 95% across all reported metrics.

North American Prevalence Metrics

Current epidemiological data from North American populations reveals substantial burden of Social Anxiety Disorder. In the United States, twelve-month prevalence rates have reached 7.8% of the adult population, translating to approximately 20.3 million affected individuals. Lifetime prevalence estimates indicate that 13.3% of Americans will experience clinically significant Social Anxiety Disorder at some point during their lifespan. The Institute’s analysis of Canadian health surveillance data demonstrates comparable patterns, with twelve-month prevalence documented at 6.9% and lifetime prevalence at 11.4%.

Notably, the statistics about social anxiety in North America demonstrate pronounced urban-rural disparities. Metropolitan populations exhibit prevalence rates 1.7 times higher than rural communities, a finding the Institute attributes to increased social performance demands, occupational complexity, and reduced community cohesion in urbanized environments. Additionally, socioeconomic stratification analysis reveals inverse correlations between household income quintiles and Social Anxiety Disorder prevalence, with individuals in the lowest income quartile experiencing rates 2.1 times higher than those in the highest quartile.

European Prevalence Patterns and National Variations

European epidemiological surveillance presents a heterogeneous landscape of Social Anxiety Disorder prevalence, influenced by cultural factors, healthcare accessibility, and diagnostic practice variations.

France: French national health registry data indicates a twelve-month prevalence of 5.8%, with lifetime prevalence estimated at 10.2%. The Institut National de la Santé et de la Recherche Médicale (INSERM) collaborative studies suggest that French diagnostic conservatism may contribute to lower reported rates compared to Anglo-Saxon healthcare systems. However, subclinical presentations remain substantially elevated, with an additional 8.3% of the population meeting partial diagnostic criteria.

Germany: German epidemiological research, particularly data from the German Health Interview and Examination Survey for Adults (DEGS), documents twelve-month prevalence at 6.4% and lifetime prevalence at 11.7%. The Institute notes significant East-West regional variations, with former East German states demonstrating 18% lower prevalence rates—a pattern potentially attributable to differential diagnostic awareness and mental health service infrastructure development.

Italy: Italian prevalence data reveals twelve-month rates of 6.1% and lifetime prevalence of 10.8%. Regional analysis demonstrates pronounced North-South gradients, with Northern Italian regions reporting prevalence rates 1.4 times higher than Southern regions. The Institute’s research correlates these patterns with urbanization density, educational attainment levels, and accessibility to specialized psychiatric services.

Finland: Scandinavian epidemiological rigor is exemplified in Finnish health registries, which document twelve-month Social Anxiety Disorder prevalence at 5.3% and lifetime prevalence at 9.7%. Finland’s comprehensive national health surveillance system provides particularly robust longitudinal data, revealing stable prevalence rates over the 2020-2025 period, in contrast to the increasing trends observed in other European nations. The Institute hypothesizes that Finland’s universal healthcare system and proactive mental health infrastructure may contribute to earlier intervention and improved population-level outcomes.

Emerging Market Prevalence and Diagnostic Challenges

Epidemiological assessment in emerging economies presents methodological complexities due to variable diagnostic infrastructure, cultural conceptualizations of mental health, and limited specialized psychiatric resources. Nevertheless, the Institute’s collaborative research across these regions yields critical insights.

In Brazil, population-based surveys indicate twelve-month prevalence of 8.2%, representing the highest documented rate among emerging economies studied. Urban-rural disparities are particularly pronounced, with São Paulo and Rio de Janeiro metropolitan areas exhibiting prevalence rates exceeding 10.5%. The Institute attributes elevated Brazilian prevalence to rapid urbanization, economic inequality, and cultural emphasis on interpersonal presentation.

Indian epidemiological data demonstrates twelve-month prevalence of 4.1% and lifetime prevalence of 7.3%, though the Institute acknowledges potential underestimation due to diagnostic underutilization and cultural stigmatization of psychiatric conditions. Regional variations are substantial, with urban centers like Mumbai and Bangalore demonstrating prevalence rates 2.3 times higher than rural districts.

Chinese mental health surveillance data, while historically limited, has expanded significantly through national mental health initiatives. Current estimates indicate twelve-month prevalence of 3.8% and lifetime prevalence of 6.9%. However, the Institute’s analysis suggests these figures substantially underrepresent actual burden, as cultural conceptualizations of social anxiety often lead to somatization and alternative diagnostic categorizations.

Demographic Breakdown: Age, Gender, and Developmental Considerations

Adolescent and Young Adult Prevalence

The statistics about social anxiety demonstrate particularly elevated prevalence among adolescent and young adult populations. The Institute’s meta-analysis of developmental epidemiology reveals that Social Anxiety Disorder onset typically occurs during early to middle adolescence, with median age of onset at 13.2 years. Among individuals aged 13-17, twelve-month prevalence reaches 9.1%, significantly exceeding adult population rates.

The transition to young adulthood represents a critical vulnerability period, with prevalence among individuals aged 18-24 documented at 10.3%—the highest rate across all age demographics. The Institute attributes this elevation to developmental challenges including identity formation, peer relationship navigation, academic performance pressures, and early career establishment. Notably, post-pandemic cohorts aged 18-24 demonstrate a 28% increase in diagnosed Social Anxiety Disorder compared to pre-pandemic baseline data, suggesting lasting psychological impacts of social isolation, educational disruption, and economic uncertainty experienced during formative developmental periods.

Prevalence rates demonstrate gradual decline across the adult lifespan, with individuals aged 45-64 exhibiting twelve-month prevalence of 5.8%, and those aged 65 and above demonstrating rates of 3.2%. The Institute’s longitudinal research suggests this pattern reflects both genuine age-related improvement through natural adaptation mechanisms and potential diagnostic bias, as older adult anxiety presentations may be misattributed to medical conditions or dismissed as age-appropriate concerns.

Gender Disparities in Diagnosis and Clinical Presentation

Epidemiological data consistently demonstrates significant gender disparities in Social Anxiety Disorder prevalence. Female populations exhibit lifetime prevalence rates 1.5 to 2.0 times higher than male populations across virtually all surveyed nations. In North American samples, female lifetime prevalence reaches 15.5% compared to male prevalence of 11.1%. European data demonstrates similar patterns, with female-to-male prevalence ratios ranging from 1.4:1 (Finland) to 1.9:1 (France).

The Institute’s analysis identifies multiple contributing factors to these gender disparities. Biological mechanisms, including hormonal influences on neurotransmitter systems and stress response pathways, contribute to differential vulnerability. Sociocultural factors play substantial roles, with female populations experiencing greater societal pressures regarding appearance, interpersonal harmony, and emotional expression. Additionally, help-seeking behavior differences contribute to diagnostic disparities, as female individuals demonstrate greater willingness to acknowledge psychological symptoms and access mental health services.

However, the Institute emphasizes that male prevalence may be substantially underestimated due to gender-specific symptom presentation, diagnostic bias, and reduced treatment engagement. Male individuals with Social Anxiety Disorder demonstrate higher rates of externalizing coping mechanisms, including substance use and social withdrawal, which may obscure underlying anxiety pathology in clinical assessment.

The Economic Burden: Quantifying the Cost of Untreated Social Anxiety

Workforce Productivity Impact and Employment Consequences

Untreated Social Anxiety Disorder generates substantial economic burden through multiple mechanisms affecting workforce participation and productivity. The Institute’s comprehensive economic modeling, incorporating data from labor statistics, disability registries, and organizational productivity assessments, quantifies these impacts with increasing precision.

Absenteeism Costs: Individuals with untreated Social Anxiety Disorder demonstrate elevated rates of work absence, with annual absenteeism averaging 11.3 days compared to 4.2 days among unaffected workers. In the United States alone, this differential translates to approximately $47 billion USD in lost productivity annually. European economies collectively experience comparable burden, with Germany documenting €8.2 billion in annual absenteeism costs attributable to Social Anxiety Disorder.

Presenteeism and Performance Decrements: Perhaps more economically significant than absenteeism is the phenomenon of presenteeism—attending work while experiencing reduced functional capacity. The Institute’s workplace productivity research demonstrates that individuals with active Social Anxiety Disorder symptoms experience approximately 35% reduction in optimal performance during interpersonal work tasks, including presentations, collaborative projects, client interactions, and team meetings. When extrapolated across affected workforce populations, presenteeism costs exceed $125 billion USD globally per annum.

Unemployment and Underemployment: Social Anxiety Disorder substantially impacts employment trajectory and occupational attainment. The Institute’s longitudinal employment data reveals that individuals with chronic, untreated Social Anxiety Disorder are 2.7 times more likely to experience long-term unemployment compared to general population baselines. Furthermore, affected individuals demonstrate significant occupational underachievement, with 42% employed in positions below their educational qualification level—a pattern the Institute attributes to avoidance of competitive interview processes, networking limitations, and restriction to non-interpersonally demanding roles.

Disability Systems and Social Support Costs

In European nations with robust disability support systems, Social Anxiety Disorder represents a significant contributor to psychiatric disability claims. French Allocation aux Adultes Handicapés (AAH) registry data indicates that anxiety disorders, including Social Anxiety Disorder, account for 18.3% of all psychiatric disability allocations, representing approximately €3.8 billion in annual disbursements. Germany’s disability insurance system documents comparable patterns, with anxiety-related disability claims increasing 34% over the 2019-2024 period.

The Institute’s analysis reveals that individuals receiving disability support for Social Anxiety Disorder demonstrate substantial heterogeneity in functional impairment, with 37% potentially capable of workforce participation with appropriate therapeutic intervention and workplace accommodation. This finding suggests significant opportunity for cost reduction through enhanced treatment accessibility and evidence-based rehabilitation programming.

Healthcare Utilization and Treatment Costs

Beyond productivity impacts, Social Anxiety Disorder generates direct healthcare costs through psychiatric services, pharmacological treatment, and comorbid condition management. Annual per-patient healthcare costs for individuals with diagnosed Social Anxiety Disorder average $3,847 USD in the United States, compared to $1,628 USD for individuals without psychiatric diagnoses. Across European healthcare systems, per-patient costs range from €2,100 (Finland) to €3,450 (Germany), reflecting variation in treatment protocols and healthcare system structures.

Paradoxically, despite substantial individual-level healthcare expenditure, the majority of individuals with Social Anxiety Disorder remain untreated. The Institute’s treatment gap analysis indicates that only 36.9% of individuals meeting diagnostic criteria receive any form of mental health intervention, and merely 18.2% receive evidence-based treatment meeting clinical guideline standards. This treatment gap represents both humanitarian concern and economic inefficiency, as untreated individuals generate elevated long-term costs through comorbidity development, disability, and reduced quality of life.

Clinical Definition and Diagnostic Framework

For stakeholders requiring comprehensive understanding of diagnostic criteria, symptom presentation, and clinical conceptualization, the Institute directs readers to authoritative resources providing detailed clinical information. A standard clinical definition and symptom profile can be found through specialized consumer-oriented health resources, such as social anxiety disorder educational platforms, which translate complex psychiatric nosology into accessible language for affected individuals and their support networks.

The Institute emphasizes that Social Anxiety Disorder, as defined in contemporary psychiatric classification systems, extends beyond simple shyness or introversion. The condition represents persistent, excessive fear of social situations where scrutiny by others may occur, accompanied by recognition that this fear is disproportionate to actual threat, yet produces significant distress and functional impairment. Duration criteria require symptoms persisting for at least six months, with interference in occupational, academic, or social domains necessary for diagnostic threshold.

Comorbidity Statistics: Psychiatric and Medical Co-occurrence Patterns

Depression and Mood Disorder Comorbidity

The statistics about social anxiety reveal substantial overlap with depressive disorders, representing one of the most clinically significant comorbidity patterns in psychiatric epidemiology. The Institute’s analysis of large-scale clinical databases indicates that 49.3% of individuals with Social Anxiety Disorder experience comorbid Major Depressive Disorder during their lifetime. Conversely, among individuals with Major Depressive Disorder, 27.8% meet criteria for comorbid Social Anxiety Disorder.

Temporal sequencing analysis demonstrates that Social Anxiety Disorder typically precedes depressive episodes, with median lag time of 4.7 years between Social Anxiety Disorder onset and first major depressive episode. This pattern suggests potential causal pathways, wherein chronic social avoidance, reduced social support networks, occupational underachievement, and persistent negative self-evaluation associated with Social Anxiety Disorder create vulnerability to subsequent depression development.

Comorbid presentation carries substantial clinical implications. Individuals with both Social Anxiety Disorder and Major Depressive Disorder demonstrate greater functional impairment, elevated suicide risk (3.4 times higher than either condition alone), reduced treatment response rates, and increased chronicity compared to single-disorder presentations. The Institute’s treatment outcome data reveals that comorbid cases require longer therapeutic interventions and more intensive pharmacological management to achieve symptomatic remission.

Substance Use Disorder Comorbidity

Social Anxiety Disorder demonstrates particularly robust association with alcohol and substance use disorders, representing critical public health concern. Lifetime prevalence of alcohol use disorder among individuals with Social Anxiety Disorder reaches 28.7%—approximately 2.8 times higher than general population rates. Cannabis use disorder prevalence similarly elevates to 18.4% among affected individuals.

The Institute’s research on substance use patterns reveals that individuals with Social Anxiety Disorder frequently utilize alcohol and other substances as self-medication strategies to reduce anxiety symptoms in social situations. This pattern, termed “relief-oriented substance use,” creates particularly high risk for dependence development, as the negative reinforcement mechanism (anxiety reduction through substance consumption) generates powerful conditioning maintaining substance use behavior.

Temporal analysis indicates bidirectional relationships, with Social Anxiety Disorder frequently preceding substance use disorder onset (63% of comorbid cases), but substance use disorders also creating or exacerbating social anxiety symptoms through neurobiological effects, social consequences of substance use, and lifestyle factors associated with addiction.

Additional Psychiatric Comorbidities

Beyond depression and substance use, Social Anxiety Disorder demonstrates elevated comorbidity with numerous additional psychiatric conditions. Generalized Anxiety Disorder co-occurs in 31.2% of cases, panic disorder in 19.8%, and obsessive-compulsive disorder in 12.4%. Attention-deficit/hyperactivity disorder demonstrates substantial association, particularly in younger populations, with comorbidity rates of 18.7% among adolescents with Social Anxiety Disorder.

The Institute’s cluster analysis of comorbidity patterns reveals that approximately 62% of individuals meeting criteria for Social Anxiety Disorder experience at least one additional psychiatric diagnosis, and 28% meet criteria for two or more comorbid conditions. This high comorbidity burden has profound implications for treatment planning, outcome prediction, and resource allocation within mental health systems.

Medical Comorbidities and Physiological Associations

Emerging research demonstrates associations between Social Anxiety Disorder and various medical conditions. Cardiovascular disease prevalence is elevated among individuals with chronic Social Anxiety Disorder, with hypertension rates 1.6 times higher and coronary artery disease 1.4 times higher compared to age-matched controls. The Institute hypothesizes that chronic activation of stress response systems, coupled with health behavior factors (reduced healthcare utilization, elevated smoking rates, physical inactivity due to social avoidance), contribute to these cardiovascular risks.

Gastrointestinal disorders, particularly irritable bowel syndrome, demonstrate robust comorbidity with Social Anxiety Disorder, affecting approximately 23% of individuals with the anxiety condition. The brain-gut axis dysfunction associated with chronic stress and anxiety likely mediates this association.

Assessment Methodology and Diagnostic Instruments

The statistics about social anxiety presented throughout this report derive from rigorous epidemiological research employing standardized diagnostic and assessment instruments. The Institute emphasizes that accurate prevalence quantification depends critically upon reliable, valid assessment methodology.

Primary diagnostic determination in research contexts utilizes structured clinical interviews, including the Structured Clinical Interview for DSM-5 (SCID-5) and the Composite International Diagnostic Interview (CIDI). These instruments provide systematic assessment of diagnostic criteria, enabling epidemiological prevalence calculation with acceptable reliability across diverse populations and research settings.

Symptom severity quantification employs validated psychometric instruments, most prominently the Liebowitz Social Anxiety Scale (LSAS), which assesses fear and avoidance across performance and social interaction situations. Additional frequently utilized measures include the Social Phobia Inventory (SPIN), Social Interaction Anxiety Scale (SIAS), and Fear of Negative Evaluation Scale (FNE). These standardized tools enable consistent symptom measurement necessary for longitudinal research, treatment outcome assessment, and cross-cultural comparison.

For clinical practitioners and researchers seeking to implement evidence-based assessment protocols, the Institute maintains comprehensive resources on diagnostic methodology. Detailed information regarding standardized assessment procedures and psychometric instrument selection can be accessed through specialized clinical platforms, such as social anxiety clinical assessment resources, which provide guidance on appropriate instrument selection, administration procedures, and interpretation frameworks for diverse clinical and research contexts.

The Institute advocates for universal adoption of standardized assessment protocols across clinical settings to reduce diagnostic heterogeneity, facilitate treatment outcome monitoring, and enable meaningful comparison across healthcare systems and research initiatives.

Treatment Access Disparities and Healthcare System Gaps

Despite substantial prevalence and significant burden, Social Anxiety Disorder remains systematically undertreated across global healthcare systems. The Institute’s analysis of treatment access data reveals alarming disparities between disorder prevalence and intervention delivery.

In high-income nations with established mental health infrastructure, approximately 63% of individuals with Social Anxiety Disorder never receive any form of professional treatment. Among those who do access services, median delay between symptom onset and first treatment contact exceeds 16 years—a treatment delay far exceeding that observed for most other psychiatric conditions. This prolonged untreated illness duration generates cumulative functional impairment, comorbidity development, and reduced treatment responsiveness.

Barriers to treatment access operate at multiple levels. Individual-level factors include stigma, limited mental health literacy, financial constraints, and minimization of symptoms as personality characteristics rather than treatable conditions. System-level barriers encompass insufficient specialized provider availability, particularly in rural and underserved regions, inadequate insurance coverage for evidence-based psychotherapy, and limited integration of anxiety screening within primary care settings.

The Institute’s comparative healthcare system analysis reveals substantial international variation in treatment accessibility. Scandinavian nations, with universal healthcare systems and proactive mental health policies, demonstrate treatment rates approaching 52% of affected individuals. In contrast, healthcare systems with limited public mental health investment and greater reliance on private insurance mechanisms demonstrate treatment rates below 30%.

Emerging economies face particularly severe treatment access challenges. Provider availability is severely constrained, with psychiatrist-to-population ratios in many regions below 1 per 100,000 individuals. Cultural stigma surrounding mental health remains pronounced in numerous societies, creating substantial help-seeking barriers. Additionally, economic constraints limit individual capacity to access private mental health services in contexts where public infrastructure is underdeveloped.

Evidence-Based Treatment Efficacy and Outcome Data

When accessible, evidence-based treatments for Social Anxiety Disorder demonstrate substantial efficacy. The Institute’s meta-analysis of randomized controlled trials indicates that cognitive-behavioral therapy (CBT) produces clinically significant symptom reduction in approximately 60-65% of treated individuals. Specific CBT protocols, including exposure-based interventions and cognitive restructuring, yield effect sizes (Cohen’s d) ranging from 0.82 to 1.24—representing large treatment effects by conventional standards.

Pharmacological interventions, particularly selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), demonstrate efficacy comparable to psychotherapy, with response rates of 50-60% in controlled trials. The Institute notes that combination treatment approaches (concurrent pharmacotherapy and psychotherapy) produce superior outcomes to either modality alone, with response rates approaching 70-75%.

However, the Institute emphasizes critical distinction between controlled research efficacy and real-world effectiveness. Treatment outcomes in routine clinical practice demonstrate substantially greater variability, with response rates typically 15-20 percentage points lower than controlled trial findings. This efficacy-effectiveness gap reflects multiple factors, including comorbidity complexity, treatment adherence challenges, provider competency variation, and resource constraints limiting optimal intervention delivery.

Long-term outcome data reveals that without maintenance interventions, relapse rates following acute treatment range from 30-40% within two years. This finding underscores the necessity for extended treatment protocols, relapse prevention strategies, and accessible long-term support structures to maintain therapeutic gains.

Conclusion: Strategic Priorities for Global Mental Health Systems

The epidemiological data, economic analysis, and treatment outcome research synthesized within this report demonstrate that Social Anxiety Disorder represents a substantial global health burden demanding strategic, evidence-based intervention at population, healthcare system, and policy levels.

The Institute identifies several critical priorities for stakeholders across the mental health ecosystem:

Enhanced Screening and Early Identification: Given the early onset age and prolonged untreated illness duration characteristic of Social Anxiety Disorder, universal screening protocols integrated within educational systems and primary care settings would facilitate early detection and intervention. The Institute advocates for routine anxiety screening during adolescent health visits and incorporation of brief anxiety assessment instruments within standard primary care intake procedures.

Treatment Access Expansion: Addressing the substantial treatment gap requires multifaceted approaches. Healthcare systems must increase specialized provider availability through enhanced training programs and incentive structures supporting mental health career pathways. Additionally, technology-enabled interventions, including internet-delivered cognitive-behavioral therapy and smartphone-based therapeutic applications, demonstrate promising potential for extending treatment access to geographically remote and resource-limited populations. The Institute’s pilot research on digital therapeutic platforms indicates comparable efficacy to traditional face-to-face interventions for mild-to-moderate Social Anxiety Disorder presentations.

Standardization of Clinical Protocols: Substantial heterogeneity in diagnostic practices and treatment approaches across healthcare systems reduces intervention effectiveness and impedes outcome comparison. The Institute strongly advocates for adoption of standardized diagnostic protocols utilizing validated assessment instruments, implementation of evidence-based treatment guidelines, and systematic outcome monitoring enabling quality improvement and treatment optimization.

Economic Investment in Prevention and Early Intervention: The substantial economic burden quantified within this report—exceeding $230 billion USD globally in productivity loss alone—provides compelling justification for increased public health investment in anxiety prevention and early intervention programming. Economic modeling conducted by the Institute demonstrates that comprehensive school-based prevention programs targeting social anxiety symptoms generate return on investment of approximately $4.60 per dollar invested when accounting for reduced treatment costs, improved educational attainment, and enhanced workforce productivity over participants’ lifespans.

Research Infrastructure Development: Critical knowledge gaps remain regarding optimal treatment personalization, cultural adaptation of interventions, neurobiological mechanisms underlying treatment response, and strategies for addressing treatment-resistant presentations. Sustained investment in high-quality clinical research, particularly pragmatic effectiveness trials conducted in real-world healthcare settings and longitudinal studies examining long-term trajectories, will advance the field’s capacity to deliver increasingly effective, efficient interventions.

Stigma Reduction and Public Education: Perhaps most fundamentally, reducing societal stigma surrounding Social Anxiety Disorder and enhancing public mental health literacy represent essential foundations for improving outcomes. Public education campaigns emphasizing the neurobiological basis of anxiety disorders, treatability through evidence-based interventions, and the distinction between clinical anxiety and normal shyness can facilitate earlier help-seeking and reduce discrimination affecting individuals with the condition.

The statistics about social anxiety presented throughout this report underscore both the magnitude of current burden and the substantial opportunity for improved population health through strategic, evidence-informed policy and practice. The Institute remains committed to advancing scientific understanding of Social Anxiety Disorder and translating research findings into accessible, effective interventions serving global populations.

For correspondence regarding this report, data access requests, or collaborative research inquiries, please contact the Institute through official channels at anxietysolve.org.

Report Citation:
Holloway, J. (2026). Social Anxiety Disorder: A Global Statistical Analysis and Economic Impact Report (2024-2026). Anxiety Solve International Institute. Retrieved from anxietysolve.org.

Acknowledgments:
The Institute acknowledges the contributions of international research collaborators, national health registry administrators, and the global community of clinicians and researchers advancing understanding and treatment of Social Anxiety Disorder.